Immunological indicators of disease activity and prognosis in multiple sclerosis

Current Opinion in Neurology

Volumn 15, Issue 3, 2002, Pages 233-237

  Galboiz, Yanina ^a   Miller, Ariel ^a  

^a CARMEL MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC PROTEIN; BIOLOGICAL MARKER; CYTOKINE; MATRIX METALLOPROTEINASE; MYELIN; URIC ACID;

DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; IMMUNOLOGY; IMMUNOPATHOGENESIS; MULTIPLE SCLEROSIS; PROGNOSIS; REVIEW;

ANTIGENS, SURFACE; BIOLOGICAL MARKERS; CYTOKINES; HUMANS; IMMUNE SYSTEM; MATRIX METALLOPROTEINASES; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; URIC ACID;

EID: 0036260596     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200206000-00002     Document Type: Review

References (62)

1. Immunopathogenesis of multiple sclerosis: The role of T cells
2. Blood-brain-barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study
3. + T cells in a model for multiple sclerosis
4. Immune-mediated demyelination
5. Matrix metalloproteinases in immunity
6. Molecular pathogenesis of multiple sclerosis
7. The natural history of multiple sclerosis: A geographically based study. 1. Clinical course and disability
8. Primary progressive multiple sclerosis. A review
9. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
10. How early can we estimate transition into the progressive course from relapsing remitting multiple sclerosis
11. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy
12. Patterns of brain magnetic resonance abnormalities on T2-weighted spin echo images in clinical subgroups of multiple sclerosis: A large cross-sectional study
13. Increased interleukin-12 production in progressive multiple sclerosis: Induction by activated CD4+ T cells via CD40 ligand
14. Cytokine and IL-12 receptor mRNA discriminate between different clinical subtypes in multiple sclerosis
15. Cytokine therapy
16. Interferon-β in multiple sclerosis: Altering the balance of interleukin-12 and interleukin-10
17. Increased percentage of IL-12+ monocytes in the blood correlates with the presence of active MRI lesions in MS
18. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesion
19. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis
20. Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis
21. Increased release of interleukin-12p40 in MS: Association with intracerebral inflammation
22. Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: Does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment?
23. Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing remitting MS
24. Treatment of multiple sclerosis with copolymer-1 (Copaxone®): Implicating mechanisms of Th1 to Th2/Th3 immune-deviation
25. Interferon (IFN)-beta treatment enhances CD95 and interleukin-10 expression but reduces interferon-gamma producing T cells in MS patients
26. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis
27. Immunomodulatory effects of interferon beta-1a in multiple sclerosis
28. The role of costimulation in autoimmune demyelination
29. Regulation of self-tolerance by CD80/CD86 interactions
30. Elevated CD40 ligand expressing blood T-cell levels in multiple sclerosis are reversed by interferon-beta treatment
31. The B7-CD28/CTLA-4 costimulatory pathways in autoimmune disease of the central nervous system
32. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system
33. Costimulatory molecules B7-1 and B7-2 on CSF cells in multiple sclerosis and optic neuritis
34. Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy
35. CD80 (B7-1) and CD86 (B7-2) expression in multiple sclerosis patients: Clinical subtype specific variation in peripheral monocytes and B cells and lack of modulation by high dose methylprednisolone
36. The co-stimulatory molecules CD28, CD40, CD40L, CD80 and CD86 as markers of disease subtype and response to interferon-β therapy in relapsing and progressive multiple sclerosis
37. Increased T cell expression of CD154 (CD40-ligand) in multiple sclerosis
38. HLA-DRB1 and disease outcome in multiple sclerosis
39. HLA-DR15 is associated with female sex and younger age at diagnosis of multiple sclerosis
40. Matrix metalloproteinases: Structure, evolution, and diversification
41. Matrix metalloproteinases and TIMPs: Properties and implications for the rheumatic diseases
42. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-β therapy in relapsing and secondary multiple sclerosis patients
43. Matrix metalloproteinases in the normal human central nervous system, microglial nodules and multiple sclerosis lesions
44. The expression of tissue type plasminogen activator, matrix metalloproteinases and endogenous inhibitors in the central nervous system in multiple sclerosis: Comparison of stages in lesion evolution
45. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke
46. Metalloproteinaese and their tissue inhibitors in multiple sclerosis
47. Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis
48. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis
49. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis
50. The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system
51. The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis
52. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: Relation to blood-brain barrier injury
53. Changes of serum sICAM-1 and MMP-9 induced by rIFNβ-1b treatment in relapsing-remitting MS
54. Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability
55. The role of uric acid in protection against peroxynitrite-mediated pathology
56. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis
57. Uric acid levels in sera from patients with multiple sclerosis
58. Increase in serum levels of uric acid, endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis
59. Monitoring progression of multiple sclerosis: p-cresol sulfate is the dominant component of urine myelin basic protein-like material
60. p-Cresol sulfate is the dominant component of urine myelin basic protein like material
61. Clinical and laboratory features of primary progressive and secondary progressive multiple sclerosis
62. Relationship of urine myelin basic protein-like material with cranial magnetic resonance imaging in advanced multiple sclerosis